Background
Burroughs Wellcome held patents on AZT (azidothymidine, branded as Retrovir®), the first antiretroviral drug approved by the FDA to treat HIV/AIDS. The patents were crucial because AZT had transformed AIDS from a uniformly fatal diagnosis to a manageable disease for many patients. Barr Laboratories, a generic drug company, sought to market generic AZT by challenging the Burroughs Wellcome patents, arguing that the government scientists at the National Cancer Institute (NCI) who had tested AZT on HIV-infected cells — before Burroughs Wellcome filed its patent applications — had actually conceived the patented invention, making them inventors and giving the government prior inventor status.
The NCI scientists had obtained AZT from Burroughs Wellcome, tested it against HIV, and discovered that it inhibited viral replication — and then shared those results with Burroughs Wellcome, which filed the patent applications. Barr argued the NCI scientists’ testing constituted conception of the claimed use of AZT to treat HIV, defeating Burroughs Wellcome’s priority.
The Court’s Holding
The Federal Circuit held for Burroughs Wellcome. The court clarified that conception in patent law requires a definite and permanent idea of the complete and operative invention — including the specific combination of drug and therapeutic use claimed. Crucially, conception must occur before corroborating experimental work; an inventor cannot conceive after the fact based on results obtained during testing that was itself guided by another’s conception.
The court found that Burroughs Wellcome’s scientists had conceived the idea of using AZT to treat HIV before sending the compound to NCI for biological testing. The NCI scientists’ role — testing AZT to confirm that it worked — was reduction to practice of Burroughs Wellcome’s conception, not independent conception. Testing a compound provided by another to discover whether it has an activity conceived by the provider is not inventive conception; it is experimental reduction to practice of the provider’s idea.
Key Takeaways
- Conception in patent law requires a definite, complete, and operative mental picture of the claimed invention — a vague or incomplete idea does not constitute conception, even if followed by successful experimental confirmation.
- Testing a compound provided by another party — to discover whether it has a particular activity — constitutes reduction to practice of the provider’s conception, not independent conception by the tester.
- Priority disputes in pharmaceutical research frequently turn on documentary evidence of when the conception occurred and who held it — laboratory notebooks, invention disclosure forms, and contemporaneous communications are critical.
- Government researchers who test industry compounds under cooperative research arrangements should document carefully whether they are reducing to practice another’s conceived invention or independently conceiving their own — the distinction determines inventorship.
Why It Matters
Burroughs Wellcome v. Barr was decided at a critical moment in the AIDS epidemic, when AZT was the only approved antiretroviral therapy and patent exclusivity controlled whether generic competition could reduce its price. The Federal Circuit’s ruling preserved Burroughs Wellcome’s patent exclusivity — and with it, the commercial foundation for continued investment in HIV drug development — by clearly allocating the conception to the industry scientists who first identified the therapeutic use, rather than the government scientists who confirmed it experimentally.
The case’s contribution to patent law on conception and reduction to practice has endured well beyond the HIV context. In an era of extensive government-industry research collaboration in pharmaceutical and biotechnology research, the principles articulated in Burroughs Wellcome v. Barr remain essential guidance for allocating inventorship and priority rights in joint research programs — with direct implications for licensing strategy, patent ownership disputes, and Bayh-Dole Act compliance.